NSW Pharmaceutical Science Group

The NSW Pharmaceutical Science Group was established in 1959 to “promote the dissemination and exchange of scientific and technical knowledge, particularly related to the Pharmaceutical Sciences”.

The Group has pursued this objective by the regular organisation of seminars with a panel of expert presenters. The presentations address specific topics or themes as variously applying to production, quality assurance, laboratory, regulatory and R&D of therapeutic goods.

Upcoming Events

 To be advised.

Past Events

Expand to view available recordings and presentations

• Clinical Trials – Expertises, Resources, Collaborative Partnerships and Product Supply - Wednesday 5 October 2022 
Dr Duncan Macinnis, Director of Stakeholder Engagement (NSW/ACT), MTPConnect
   
Clinical Trials in Drug Development
Judy Bingham, Executive Director, Easington Pty Ltd 

GMP and other documentary requirements and guidelines for APIs and dose form
David Edmonds, former Principal, CMC Regulatory

From Bench to Clinic – Translating a new therapeutic into a commercially viable product for clinical trial
Prof Paul Young, CEO, AB Initio Pharma

Manufacture and Quality Requirements of NMEs/APIs for Clinical Trials
Dr Jurgen Lindner, Executive Secretary, APIMAA (Active Pharmaceutical Ingredient Manufacturers’
Association of Australia)

Specifications, Manufacture and Quality Requirements of Dose Form and Placebos for Clinical Trials
Craig Rogers, Director, Syntro Health

Note:
The TGA presentation is not available to be posted on this website.
A recording of this webinar, not including the TGA content, may be found at 




• Establishing and Maintaining Data Integrity - Tuesday 25 October 2022

• Data from a computational astrochemist
  Dr Laura McKemmish, Senior Lecturer, School of Chemistry, UNSW
  
  TGA Requirements
  Gaye Camm, Senior Inspector, Manufacturing and Quality Branch, TGA
  
  Data integrity – Documentation – Batch documentation SOPs, logs etc
  Trevor Schoerie, Managing Director,  PharmOut
  
  Data Integrity – equipment
  Seamus Orr, Technical Services Manager, AstraZeneca
  
  Coding creation and scanning
  Bruce Botta, Packaging Technical Coordinator, Aspen Australia
  
  The Data Integrity Challenges of Analytical Instrumentation
  Clayton Ross, Business development manager, Shimadzu
  
  Data Protection
  Ian Ward, Managing Director, CyberPro Pty Ltd
  
  The TGA presentation is posted on the TGA website.
  
  A recording of this webinar, not including the TGA content, may be found at ?
  

   

  •     Hybrid Audits - Thursday 1 December 2022
  Matthew Bugg

  Quality Manager, Australia & New Zealand, BeiGene
  
  A recording of this webinar may be found at ?
  

   

  
  
  
• PSG NSW Presents Building the RNA Ecosystem July 2022
  Click here to see webinar recording
  
  
• Preservatives and Preservatives efficacy Seminar March 2022
  
  • Presentation 1 - Preservative Types and Formulation of products
    
  • Presentation 2 - PET - Microbiological analysis, traditional and rapid techniques
  • Presentation 3 - PET - Microbiological analysis, traditional and rapid techniques 
    
  • Presentation 4 - The Chemistry and Analysis of Preservatives
  • Download Presentation 1
    
  • Download Presentation 2
    
  • Download Presentation 3
    
  • Download Presentation 4
    
    
• Therapeutic Goods Labelling - Data Coding and Serialisation November 2021
  
  Presenters 1 : Dr Tony Manderson, Director, Scientific Operations Management Section, TGA 
  •   Presenter 2: Catherine Koetz Industry Manager – Healthcare GS1 Australia Ltd 
  •  Presenter 3 : Michael Hadjion, Engineering Manager. Aspen Pharma Australia
    
  • Presenter 4: Richard Driscoll, Traceability lead, AstraZeneca
  • Presenter 5: Peter Barclay, Head of Department, Pharmacy, Sydney Children's Hospital, Westmead
  • Download Standards Behind Standards Presentation
  • Download Implementation and Operation
  • Download An End User Perspective
  • Download Aggregation and Data Accuracy within Serialised Systems
    

  • Click here to see part 1 of the webinar recording
    

  •  Click here to see part 2 of the webinar recording

• Drug Delivery for the Treatment of Children's Cancer September 2021

  • Presenter : Prof. Maria Kavallaris AM, Founding Director, the Australian Centre for NanoMedicine, UNSW Sydney and Head, Translational Cancer Nanomedicine, Children’s Cancer Institute.

  • Click here to see webinar recording 
    
    

• Delivery system for mRNA Covid 19 vaccine  Virtual Event On Wednesday  February 2021

  • Presenter:- Dr Andrew Geall, CEO RNA Consulting, LLC and Chief Scientific Officer of Precision NanoSystems Inc. (PNI)

    Click here to download presentation 
    
    

• Euclidating Vaccine Formulation Stability May 2021 Webinar

  • Click here to see webinar recording
    
    

• Ingredient Supply and Change of Sources for Medicine Manufacture Monday  December 2020

  • Presentation 1 :- ARTG Variations to support market supply: TGA’s experience with prescription medicines during COVID-19

    Presentation 2: Supply Specifications

    David Edmonds, Former Principal CMC Consulting

    Presentation link Supply and specifications DE

     

    Presentation 3 :- 6 Months on – lessons learned and the future - Perspective from a Life Science industry supplier & leader: Merck

    Rebecca Lee, ANZ Managing Director, Merck

    Click here to download presentation 

    Click here to see webinar recording
    
    

• Aspects of the Science of COVID-19 – Treatment Virtual Event On Thursday October 2020

  • 1.) COVID-19: Developing Vaccines at Pandemic Speed

  • ----- ----- Natalie Kahwajy, Senior Pharmacist (Antimicrobial Stewardship), Bankstown-Lidcombe Hospital

  • 2.) COVID-19: Treatment: Dexamethasone

  • ----- Ms Renee Faraj - Senior Regulatory Affairs Associate

  • 3.)COVID-19: Treatment: Remdesimir

  • ----- -----Prof Jan-Willem Alffenaar, Chair of Clinical Pharmacy, The University of Sydney, Faculty of Medicine and Health, School of Pharmacy and Westmead Hospital

  Recording available here
  
  

• Remote auditing - Impact of Covid-19 restrictions on manufacturers and test laboratories September 2020

  • Webinar moderator and host:              

  • 1.) Remote auditing – from TGA MQB perspective

  • ----- ----- Ms Lynn Talomsin, Senior Inspector/Technical Specialist, Manufacturing Quality Branch, TGA

  • 2.) Remote auditing – from an auditee perspective

  • ----- Ms Melanie Richter, Quality Compliance Specialist, AstraZeneca

  • 3.) Auditing and other GMP experiences in the Covid-19 era – US perspective

  • ----- -----Ms Maxine Fritz, Executive Vice President, Pharmaceutical Services, NSF International

  Recording available here

  NOTE:- The TGA presentation is unavailable on this site and has yet to be posted on the TGA website.

  Click here to Download AZ Remote Audits (RACI)

  Click here to Download NSF - Consulting Issues during Covid-19
  
  

• Aspects of the Science of COVID-19 (3) - Vaccines  - Virtual Event July 2020

  • Webinar moderator and host:  

  • Mrs Niesha Davis, RACI Pharmaceutical Science Group (NSW) Committee and Learning and Development, Technical Manager, AstraZeneca

  • 1.) COVID-19: Developing Vaccines at Pandemic Speed

  • ----- Prof Trent Munro, Senior Group Leader, The Australian Institute for Bioengineering and Nanotechnology

  • 2.) Steps for vectored vaccines as solutions to rapid development of vaccines

  • ----- Dr Paul Howley, Managing Director, Vaxmed Pty Ltd

  Recording available here
  
  
  

• Aspects of the Science of COVID-19 (1) Virtual Event  May 2020

  • 1.) Medicinal Chemistry - How do antiviral drugs work? Are there any antiviral drugs for COVID-19?

  • -----  Dr Derek Lowe, Director in Chemical Biology Therapeutics, Novartis Institutes for BioMedical Research

  •  

    2.)Photochemistry of nucleic acids - Why does UV exposure destroy COVID-19

  • ---- A/Prof Tak Kee, Department of Chemistry, University of Adelaide

    Recording available here
    
    
    

• How is the Pharmaceutical sector dealing with COVID-19  Virtual Event  April 2020

  • 1.) Laboratory perspective.   -----  Alan Doughty, CEO Chemika

    2.)Perspective from a Life Science industry supplier & leader: Merck. ---- Rebecca Lee, ANZ Managing Director, Merck

    3.) Medicine manufacturer’s Perspective.  ---- Gary Lay, Procurement manager, AstraZeneca

  Recording available here